[A21-88] Glecaprevir/pibrentasvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2021
Project no.:
A21-88
Commission:
Commission awarded on 30.06.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Children aged 3 to < 12 years with chronic HCV infection
Result of dossier assessment:
- Genotype 1, 4, 5 or 6: added benefit not proven.
- Genotype 2 or 3: added benefit not proven.
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A19-33 | Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-34 | Glecaprevir/pibrentasvir (chronic hepatitis C) – Benefit assessment according to § 35a Social Code Book V | Commission completed |